ID   DGKE_HUMAN              Reviewed;         567 AA.
AC   P52429; Q8TBM4; Q9UKQ3;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   28-JUN-2023, entry version 194.
DE   RecName: Full=Diacylglycerol kinase epsilon;
DE            Short=DAG kinase epsilon;
DE            EC=2.7.1.107 {ECO:0000269|PubMed:15544348, ECO:0000269|PubMed:18004883, ECO:0000269|PubMed:19744926, ECO:0000269|PubMed:21477596, ECO:0000269|PubMed:22108654, ECO:0000269|PubMed:23949095};
DE   AltName: Full=Diglyceride kinase epsilon;
DE            Short=DGK-epsilon;
GN   Name=DGKE; Synonyms=DAGK5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RC   TISSUE=Umbilical vein endothelial cell;
RX   PubMed=8626589; DOI=10.1074/jbc.271.17.10230;
RA   Tang W., Bunting M., Zimmerman G.A., McIntyre T.M., Prescott S.M.;
RT   "Molecular cloning of a novel human diacylglycerol kinase highly selective
RT   for arachidonate-containing substrates.";
RL   J. Biol. Chem. 271:10237-10241(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-154.
RX   PubMed=10571048; DOI=10.1016/s0378-1119(99)00345-5;
RA   Tang W., Bardien S., Bhattacharya S.S., Prescott S.M.;
RT   "Characterization of the human diacylglycerol kinase epsilon gene and its
RT   assessment as a candidate for inherited retinitis pigmentosa.";
RL   Gene 239:185-192(1999).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, AND PATHWAY.
RX   PubMed=15544348; DOI=10.1021/bi0484724;
RA   Epand R.M., Kam A., Bridgelal N., Saiga A., Topham M.K.;
RT   "The alpha isoform of diacylglycerol kinase exhibits arachidonoyl
RT   specificity with alkylacylglycerol.";
RL   Biochemistry 43:14778-14783(2004).
RN   [6]
RP   CATALYTIC ACTIVITY.
RX   PubMed=18004883; DOI=10.1021/bi701584v;
RA   Epand R.M., Shulga Y.V., Timmons H.C., Perri A.L., Belani J.D.,
RA   Perinpanathan K., Johnson-McIntire L.B., Bajjalieh S., Dicu A.O., Elias C.,
RA   Rychnovsky S.D., Topham M.K.;
RT   "Substrate chirality and specificity of diacylglycerol kinases and the
RT   multisubstrate lipid kinase.";
RL   Biochemistry 46:14225-14231(2007).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, AND ACTIVITY
RP   REGULATION.
RX   PubMed=19744926; DOI=10.1074/jbc.m109.050617;
RA   Lung M., Shulga Y.V., Ivanova P.T., Myers D.S., Milne S.B., Brown H.A.,
RA   Topham M.K., Epand R.M.;
RT   "Diacylglycerol kinase epsilon is selective for both acyl chains of
RT   phosphatidic acid or diacylglycerol.";
RL   J. Biol. Chem. 284:31062-31073(2009).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBSTRATE SPECIFICITY.
RX   PubMed=22108654; DOI=10.1016/j.febslet.2011.11.016;
RA   Shulga Y.V., Topham M.K., Epand R.M.;
RT   "Substrate specificity of diacylglycerol kinase-epsilon and the
RT   phosphatidylinositol cycle.";
RL   FEBS Lett. 585:4025-4028(2011).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LEU-431; LEU-438 AND
RP   PRO-439.
RX   PubMed=21477596; DOI=10.1016/j.jmb.2011.03.071;
RA   Shulga Y.V., Topham M.K., Epand R.M.;
RT   "Study of arachidonoyl specificity in two enzymes of the PI cycle.";
RL   J. Mol. Biol. 409:101-112(2011).
RN   [10]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=23949095; DOI=10.1159/000351849;
RA   Sato M., Liu K., Sasaki S., Kunii N., Sakai H., Mizuno H., Saga H.,
RA   Sakane F.;
RT   "Evaluations of the selectivities of the diacylglycerol kinase inhibitors
RT   R59022 and R59949 among diacylglycerol kinase isozymes using a new non-
RT   radioactive assay method.";
RL   Pharmacology 92:99-107(2013).
RN   [11]
RP   INVOLVEMENT IN NPHS7.
RX   PubMed=23274426; DOI=10.1681/asn.2012090903;
RA   Ozaltin F., Li B., Rauhauser A., An S.W., Soylemezoglu O., Gonul I.I.,
RA   Taskiran E.Z., Ibsirlioglu T., Korkmaz E., Bilginer Y., Duzova A., Ozen S.,
RA   Topaloglu R., Besbas N., Ashraf S., Du Y., Liang C., Chen P., Lu D.,
RA   Vadnagara K., Arbuckle S., Lewis D., Wakeland B., Quigg R.J., Ransom R.F.,
RA   Wakeland E.K., Topham M.K., Bazan N.G., Mohan C., Hildebrandt F.,
RA   Bakkaloglu A., Huang C.L., Attanasio M.;
RT   "DGKE variants cause a glomerular microangiopathy that mimics
RT   membranoproliferative GN.";
RL   J. Am. Soc. Nephrol. 24:377-384(2013).
RN   [12]
RP   TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND VARIANTS AHUS7 PRO-63 AND
RP   PRO-273.
RX   PubMed=23542698; DOI=10.1038/ng.2590;
RA   Lemaire M., Fremeaux-Bacchi V., Schaefer F., Choi M., Tang W.H.,
RA   Le Quintrec M., Fakhouri F., Taque S., Nobili F., Martinez F., Ji W.,
RA   Overton J.D., Mane S.M., Nuernberg G., Altmueller J., Thiele H., Morin D.,
RA   Deschenes G., Baudouin V., Llanas B., Collard L., Majid M.A., Simkova E.,
RA   Nuernberg P., Rioux-Leclerc N., Moeckel G.W., Gubler M.C., Hwa J.,
RA   Loirat C., Lifton R.P.;
RT   "Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome.";
RL   Nat. Genet. 45:531-536(2013).
RN   [13]
RP   VARIANT [LARGE SCALE ANALYSIS] ARG-99.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Membrane-bound diacylglycerol kinase that converts
CC       diacylglycerol/DAG into phosphatidic acid/phosphatidate/PA and
CC       regulates the respective levels of these two bioactive lipids
CC       (PubMed:15544348, PubMed:19744926, PubMed:22108654, PubMed:21477596,
CC       PubMed:23949095). Thereby, acts as a central switch between the
CC       signaling pathways activated by these second messengers with different
CC       cellular targets and opposite effects in numerous biological processes
CC       (PubMed:8626589, PubMed:15544348). Also plays an important role in the
CC       biosynthesis of complex lipids (PubMed:8626589). Displays specificity
CC       for diacylglycerol substrates with an arachidonoyl acyl chain at the
CC       sn-2 position, with the highest activity toward 1-octadecanoyl-2-
CC       (5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycerol the main diacylglycerol
CC       intermediate within the phosphatidylinositol turnover cycle
CC       (PubMed:19744926, PubMed:22108654, PubMed:23274426). Can also
CC       phosphorylate diacylglycerol substrates with a linoleoyl acyl chain at
CC       the sn-2 position but much less efficiently (PubMed:22108654).
CC       {ECO:0000269|PubMed:15544348, ECO:0000269|PubMed:19744926,
CC       ECO:0000269|PubMed:21477596, ECO:0000269|PubMed:22108654,
CC       ECO:0000269|PubMed:23274426, ECO:0000269|PubMed:23949095,
CC       ECO:0000303|PubMed:15544348, ECO:0000303|PubMed:8626589}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycerol + ATP = a 1,2-diacyl-sn-glycero-3-
CC         phosphate + ADP + H(+); Xref=Rhea:RHEA:10272, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:17815, ChEBI:CHEBI:30616, ChEBI:CHEBI:58608,
CC         ChEBI:CHEBI:456216; EC=2.7.1.107;
CC         Evidence={ECO:0000269|PubMed:15544348, ECO:0000269|PubMed:18004883,
CC         ECO:0000269|PubMed:19744926, ECO:0000269|PubMed:21477596,
CC         ECO:0000269|PubMed:22108654, ECO:0000269|PubMed:23949095};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10273;
CC         Evidence={ECO:0000305|PubMed:15544348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycerol
CC         + ATP = 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-
CC         3-phosphate + ADP + H(+); Xref=Rhea:RHEA:40335, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:72864, ChEBI:CHEBI:77096,
CC         ChEBI:CHEBI:456216; Evidence={ECO:0000269|PubMed:19744926};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40336;
CC         Evidence={ECO:0000305|PubMed:19744926};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycerol
CC         + ATP = 1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-
CC         3-phosphate + ADP + H(+); Xref=Rhea:RHEA:40323, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:75728, ChEBI:CHEBI:77091,
CC         ChEBI:CHEBI:456216; Evidence={ECO:0000269|PubMed:15544348,
CC         ECO:0000269|PubMed:18004883, ECO:0000269|PubMed:19744926,
CC         ECO:0000269|PubMed:21477596, ECO:0000269|PubMed:22108654,
CC         ECO:0000269|PubMed:23949095};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40324;
CC         Evidence={ECO:0000305|PubMed:15544348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-eicosanoyl-2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycerol +
CC         ATP = 1-eicosanoyl-2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-3-
CC         phosphate + ADP + H(+); Xref=Rhea:RHEA:40331, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:77093, ChEBI:CHEBI:77094,
CC         ChEBI:CHEBI:456216; Evidence={ECO:0000269|PubMed:19744926};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40332;
CC         Evidence={ECO:0000305|PubMed:19744926};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-di-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycerol + ATP =
CC         1,2-di-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-3-phosphate + ADP
CC         + H(+); Xref=Rhea:RHEA:40351, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:77125, ChEBI:CHEBI:77126, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000269|PubMed:22108654};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40352;
CC         Evidence={ECO:0000305|PubMed:22108654};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-octadecanoyl-2-(9Z,12Z)-octadecadienoyl-sn-glycerol + ATP =
CC         1-octadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphate +
CC         ADP + H(+); Xref=Rhea:RHEA:40339, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:77097, ChEBI:CHEBI:77098,
CC         ChEBI:CHEBI:456216; Evidence={ECO:0000269|PubMed:19744926,
CC         ECO:0000269|PubMed:22108654};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40340;
CC         Evidence={ECO:0000305|PubMed:19744926};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-di-(9Z,12Z-octadecadienoyl)-sn-glycerol + ATP = 1,2-di-
CC         (9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphate + ADP + H(+);
CC         Xref=Rhea:RHEA:40355, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:77127, ChEBI:CHEBI:77128, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000269|PubMed:22108654};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40356;
CC         Evidence={ECO:0000305|PubMed:22108654};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-di-(9Z-octadecenoyl)-sn-glycerol + ATP = 1,2-di-(9Z-
CC         octadecenoyl)-sn-glycero-3-phosphate + ADP + H(+);
CC         Xref=Rhea:RHEA:40327, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:52333, ChEBI:CHEBI:74546, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000269|PubMed:15544348, ECO:0000269|PubMed:19744926};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40328;
CC         Evidence={ECO:0000305|PubMed:15544348};
CC   -!- ACTIVITY REGULATION: Undergoes competitive inhibition by its own
CC       product 1,2-diacyl-sn-glycero-3-phosphate/phosphatidic acid. The
CC       strongest inhibition being observed in vitro with 1-octadecanoyl-2-
CC       (5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphate, a major
CC       intermediate in the phosphatidylinositol turnover cycle and more
CC       generally by diacylglycerols with an arachidonoyl acyl chain at the sn-
CC       2 position. {ECO:0000269|PubMed:19744926}.
CC   -!- PATHWAY: Lipid metabolism; glycerolipid metabolism.
CC       {ECO:0000305|PubMed:15544348}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:23542698}; Single-
CC       pass membrane protein {ECO:0000255}. Cytoplasm
CC       {ECO:0000269|PubMed:23542698}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P52429-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P52429-2; Sequence=VSP_056957, VSP_056958;
CC   -!- TISSUE SPECIFICITY: Expressed predominantly in testis. Expressed in
CC       endothelium, platelets and podocytes (at protein level).
CC       {ECO:0000269|PubMed:23542698}.
CC   -!- DISEASE: Nephrotic syndrome 7 (NPHS7) [MIM:615008]: A form of nephrotic
CC       syndrome, a renal disease clinically characterized by severe
CC       proteinuria, resulting in complications such as hypoalbuminemia,
CC       hyperlipidemia and edema. NPHS7 is an autosomal recessive form
CC       characterized by onset of proteinuria usually in the first decade of
CC       life. The disorder is progressive, and some patients develop end-stage
CC       renal disease within several years. Renal biopsy typically shows
CC       membranoproliferative glomerulonephritis.
CC       {ECO:0000269|PubMed:23274426}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Hemolytic uremic syndrome atypical 7 (AHUS7) [MIM:615008]: An
CC       atypical form of hemolytic uremic syndrome characterized by acute onset
CC       in the first year of life of microangiopathic hemolytic anemia,
CC       thrombocytopenia, and renal failure. After the acute episode, most
CC       patients develop chronic renal insufficiency. Unlike other genetic
CC       forms of aHUS, AHUS7 is not related to abnormal activation of the
CC       complement system. {ECO:0000269|PubMed:23542698}. Note=Disease
CC       susceptibility is associated with variants affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the eukaryotic diacylglycerol kinase family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U49379; AAC50497.1; -; mRNA.
DR   EMBL; AC015912; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC106858; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC022297; AAH22297.1; -; mRNA.
DR   EMBL; AF136745; AAD45666.1; -; Genomic_DNA.
DR   CCDS; CCDS11590.1; -. [P52429-1]
DR   RefSeq; NP_003638.1; NM_003647.2. [P52429-1]
DR   AlphaFoldDB; P52429; -.
DR   SMR; P52429; -.
DR   BioGRID; 114096; 71.
DR   IntAct; P52429; 23.
DR   STRING; 9606.ENSP00000284061; -.
DR   ChEMBL; CHEMBL1075187; -.
DR   DrugBank; DB14001; alpha-Tocopherol succinate.
DR   SwissLipids; SLP:000000546; -.
DR   iPTMnet; P52429; -.
DR   PhosphoSitePlus; P52429; -.
DR   SwissPalm; P52429; -.
DR   BioMuta; DGKE; -.
DR   DMDM; 1708625; -.
DR   EPD; P52429; -.
DR   jPOST; P52429; -.
DR   MassIVE; P52429; -.
DR   MaxQB; P52429; -.
DR   PaxDb; P52429; -.
DR   PeptideAtlas; P52429; -.
DR   ProteomicsDB; 56484; -. [P52429-1]
DR   ProteomicsDB; 74029; -.
DR   Antibodypedia; 2548; 269 antibodies from 30 providers.
DR   DNASU; 8526; -.
DR   Ensembl; ENST00000284061.8; ENSP00000284061.3; ENSG00000153933.10. [P52429-1]
DR   Ensembl; ENST00000572810.1; ENSP00000459295.1; ENSG00000153933.10. [P52429-2]
DR   GeneID; 8526; -.
DR   KEGG; hsa:8526; -.
DR   MANE-Select; ENST00000284061.8; ENSP00000284061.3; NM_003647.3; NP_003638.1.
DR   UCSC; uc002iur.4; human. [P52429-1]
DR   AGR; HGNC:2852; -.
DR   CTD; 8526; -.
DR   DisGeNET; 8526; -.
DR   GeneCards; DGKE; -.
DR   GeneReviews; DGKE; -.
DR   HGNC; HGNC:2852; DGKE.
DR   HPA; ENSG00000153933; Tissue enhanced (retina).
DR   MalaCards; DGKE; -.
DR   MIM; 601440; gene.
DR   MIM; 615008; phenotype.
DR   neXtProt; NX_P52429; -.
DR   OpenTargets; ENSG00000153933; -.
DR   Orphanet; 357008; Hemolytic uremic syndrome with DGKE deficiency.
DR   Orphanet; 329903; Immunoglobulin-mediated membranoproliferative glomerulonephritis.
DR   PharmGKB; PA27313; -.
DR   VEuPathDB; HostDB:ENSG00000153933; -.
DR   eggNOG; KOG1169; Eukaryota.
DR   GeneTree; ENSGT00940000158604; -.
DR   HOGENOM; CLU_1517427_0_0_1; -.
DR   InParanoid; P52429; -.
DR   OMA; MQPDCER; -.
DR   OrthoDB; 4642163at2759; -.
DR   PhylomeDB; P52429; -.
DR   TreeFam; TF313104; -.
DR   BRENDA; 2.7.1.107; 2681.
DR   PathwayCommons; P52429; -.
DR   Reactome; R-HSA-114508; Effects of PIP2 hydrolysis.
DR   SignaLink; P52429; -.
DR   UniPathway; UPA00230; -.
DR   BioGRID-ORCS; 8526; 14 hits in 1164 CRISPR screens.
DR   ChiTaRS; DGKE; human.
DR   GenomeRNAi; 8526; -.
DR   Pharos; P52429; Tbio.
DR   PRO; PR:P52429; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P52429; protein.
DR   Bgee; ENSG00000153933; Expressed in Brodmann (1909) area 23 and 170 other tissues.
DR   ExpressionAtlas; P52429; baseline and differential.
DR   Genevisible; P52429; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004143; F:diacylglycerol kinase activity; IDA:UniProtKB.
DR   GO; GO:0016301; F:kinase activity; IDA:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0046339; P:diacylglycerol metabolic process; IDA:UniProtKB.
DR   GO; GO:0046834; P:lipid phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050804; P:modulation of chemical synaptic transmission; IEA:Ensembl.
DR   GO; GO:0006654; P:phosphatidic acid biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; IEA:Ensembl.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0007205; P:protein kinase C-activating G protein-coupled receptor signaling pathway; IEA:InterPro.
DR   CDD; cd20801; C1_DGKepsilon_typeIII_rpt1; 1.
DR   CDD; cd20853; C1_DGKepsilon_typeIII_rpt2; 1.
DR   Gene3D; 2.60.200.40; -; 1.
DR   Gene3D; 3.30.60.20; -; 1.
DR   InterPro; IPR017438; ATP-NAD_kinase_N.
DR   InterPro; IPR046349; C1-like_sf.
DR   InterPro; IPR037607; DGK.
DR   InterPro; IPR000756; Diacylglycerol_kin_accessory.
DR   InterPro; IPR001206; Diacylglycerol_kinase_cat_dom.
DR   InterPro; IPR016064; NAD/diacylglycerol_kinase_sf.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   PANTHER; PTHR11255; DIACYLGLYCEROL KINASE; 1.
DR   PANTHER; PTHR11255:SF54; DIACYLGLYCEROL KINASE EPSILON; 1.
DR   Pfam; PF00130; C1_1; 1.
DR   Pfam; PF00609; DAGK_acc; 1.
DR   Pfam; PF00781; DAGK_cat; 1.
DR   SMART; SM00109; C1; 2.
DR   SMART; SM00045; DAGKa; 1.
DR   SMART; SM00046; DAGKc; 1.
DR   SUPFAM; SSF57889; Cysteine-rich domain; 2.
DR   SUPFAM; SSF111331; NAD kinase/diacylglycerol kinase-like; 1.
DR   PROSITE; PS50146; DAGK; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 2.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cytoplasm; Disease variant;
KW   Hemolytic uremic syndrome; Kinase; Lipid metabolism; Membrane;
KW   Metal-binding; Nucleotide-binding; Reference proteome; Repeat; Transferase;
KW   Transmembrane; Transmembrane helix; Zinc; Zinc-finger.
FT   CHAIN           1..567
FT                   /note="Diacylglycerol kinase epsilon"
FT                   /id="PRO_0000218464"
FT   TRANSMEM        22..42
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          215..356
FT                   /note="DAGKc"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00783"
FT   ZN_FING         59..108
FT                   /note="Phorbol-ester/DAG-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   ZN_FING         124..177
FT                   /note="Phorbol-ester/DAG-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   VAR_SEQ         156..177
FT                   /note="CIWCQKTVHDECMKNSLKNEKC -> YGLRGHSLSQNAPWESGFHRVV (in
FT                   isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_056957"
FT   VAR_SEQ         178..567
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_056958"
FT   VARIANT         63
FT                   /note="R -> P (in AHUS7; dbSNP:rs312262694)"
FT                   /evidence="ECO:0000269|PubMed:23542698"
FT                   /id="VAR_069804"
FT   VARIANT         99
FT                   /note="L -> R (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036120"
FT   VARIANT         273
FT                   /note="R -> P (in AHUS7; dbSNP:rs312262695)"
FT                   /evidence="ECO:0000269|PubMed:23542698"
FT                   /id="VAR_069805"
FT   MUTAGEN         431
FT                   /note="L->I: Decreased diacylglycerol kinase activity
FT                   toward
FT                   1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycerol."
FT                   /evidence="ECO:0000269|PubMed:21477596"
FT   MUTAGEN         431
FT                   /note="L->S: Loss of diacylglycerol kinase activity toward
FT                   1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycerol."
FT                   /evidence="ECO:0000269|PubMed:21477596"
FT   MUTAGEN         438
FT                   /note="L->I: Decreased diacylglycerol kinase activity
FT                   toward
FT                   1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycerol."
FT                   /evidence="ECO:0000269|PubMed:21477596"
FT   MUTAGEN         438
FT                   /note="L->M: Decreased protein abundance and diacylglycerol
FT                   kinase activity toward
FT                   1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycerol."
FT                   /evidence="ECO:0000269|PubMed:21477596"
FT   MUTAGEN         438
FT                   /note="L->S,A,G: Loss of diacylglycerol kinase activity
FT                   toward
FT                   1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycerol."
FT                   /evidence="ECO:0000269|PubMed:21477596"
FT   MUTAGEN         439
FT                   /note="P->G: Decreased diacylglycerol kinase activity
FT                   toward
FT                   1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycerol."
FT                   /evidence="ECO:0000269|PubMed:21477596"
SQ   SEQUENCE   567 AA;  63927 MW;  BC334AD15FB4D0B4 CRC64;
     MEAERRPAPG SPSEGLFADG HLILWTLCSV LLPVFITFWC SLQRSRRQLH RRDIFRKSKH
     GWRDTDLFSQ PTYCCVCAQH ILQGAFCDCC GLRVDEGCLR KADKRFQCKE IMLKNDTKVL
     DAMPHHWIRG NVPLCSYCMV CKQQCGCQPK LCDYRCIWCQ KTVHDECMKN SLKNEKCDFG
     EFKNLIIPPS YLTSINQMRK DKKTDYEVLA SKLGKQWTPL IILANSRSGT NMGEGLLGEF
     RILLNPVQVF DVTKTPPIKA LQLCTLLPYY SARVLVCGGD GTVGWVLDAV DDMKIKGQEK
     YIPQVAVLPL GTGNDLSNTL GWGTGYAGEI PVAQVLRNVM EADGIKLDRW KVQVTNKGYY
     NLRKPKEFTM NNYFSVGPDA LMALNFHAHR EKAPSLFSSR ILNKAVYLFY GTKDCLVQEC
     KDLNKKVELE LDGERVALPS LEGIIVLNIG YWGGGCRLWE GMGDETYPLA RHDDGLLEVV
     GVYGSFHCAQ IQVKLANPFR IGQAHTVRLI LKCSMMPMQV DGEPWAQGPC TVTITHKTHA
     MMLYFSGEQT DDDISSTSDQ EDIKATE
//
